An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

获得性 HER2T798I 门控突变导致 HER2 突变驱动乳腺癌患者对 Neratinib 产生耐药性

阅读：6
作者：Ariella B Hanker, Monica Red Brewer, Jonathan H Sheehan, James P Koch, Gregory R Sliwoski, Rebecca Nagy, Richard Lanman, Michael F Berger, David M Hyman, David B Solit, Jie He, Vincent Miller, Richard E Cutler Jr, Alshad S Lalani, Darren Cross, Christine M Lovly, Jens Meiler, Carlos L Arteaga2
期刊：Cancer Discovery影响因子：29.700
时间：2017起止号：2017 Jun;7(6):575-585.
doi：10.1158/2159-8290.CD-16-1431研究方向： 肿瘤
疾病类型： 乳腺癌

Significance

We found an acquired HER2 gatekeeper mutation in a patient with HER2-mutant breast cancer upon clinical progression on neratinib. We speculate that HER2T798I may arise as a secondary mutation following response to effective HER2 tyrosine kinase inhibitors (TKI) in other cancers with HER2-activating mutations. This resistance may be overcome by other irreversible HER2 TKIs, such as afatinib. Cancer Discov; 7(6); 575-85. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 539.

Trial registration

ClinicalTrials.gov NCT01953926.

特别声明

1、本文转载旨在传播信息，不代表本网站观点，亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用，必须保留本网站注明的“来源”，并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载，或需洽谈转载稿费等事宜，请及时与本网站联系。

4、此外，如需投稿，也可通过邮箱info@biocloudy.com与我们取得联系。